enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. Pertuzumab/trastuzumab/hyaluronidase - Wikipedia

    en.wikipedia.org/wiki/Pertuzumab/trastuzumab/...

    The fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase was approved for medical use in the United States in June 2020. [5] [10]The FDA's approval was based on the results of a non-inferiority study in participants with HER2-positive early breast cancer, which demonstrated the fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase had comparable efficacy and ...

  3. Trastuzumab/hyaluronidase - Wikipedia

    en.wikipedia.org/wiki/Trastuzumab/hyaluronidase

    Trastuzumab/hyaluronidase, sold under the brand name Herceptin SC among others, is a fixed-dose combination medication for the treatment of HER2-overexpressing breast ...

  4. Trastuzumab - Wikipedia

    en.wikipedia.org/wiki/Trastuzumab

    Genentech developed trastuzumab jointly with UCLA, beginning the first clinical trial with 15 women in 1992. [77] By 1996, clinical trials had expanded to over 900 women, but due to pressure from advocates based on early success, Genentech worked with the FDA to begin a lottery system allowing 100 women each quarter access to the medication ...

  5. Pertuzumab - Wikipedia

    en.wikipedia.org/wiki/Pertuzumab

    Pertuzumab is administered as an intravenous infusion in combination with trastuzumab and docetaxel as a first line treatment for HER2-positive metastatic breast cancer. [4] [3] It is also used in the same combination as a neoadjuvant (given to reduce the size of a tumor, prior to surgery or radiation) for HER2-positive early breast cancer; as of 2016 this use had not been shown to increase ...

  6. Hyaluronidase - Wikipedia

    en.wikipedia.org/wiki/Hyaluronidase

    Elevated tissue expression of hyaluronic acid and hyaluronidase validates the hyaluronic acid-hyaluronidases urine test for bladder cancer. [48] Limited data support a role of lysosomal hyaluronidases in metastasis, while other data support a role in tumor suppression. Other studies suggest no contribution or effects independent of enzyme activity.

  7. Trastuzumab emtansine - Wikipedia

    en.wikipedia.org/wiki/Trastuzumab_emtansine

    Results showed that patients treated with trastuzumab emtansine had a median progression-free survival of 9.6 months compared to 6.4 months in patients treated with lapatinib plus capecitabine. [18] The median overall survival was 30.9 months in the trastuzumab emtansine group and 25.1 months in the lapatinib plus capecitabine group. [18]

  8. The #1 High-Protein Snack for Better Heart Health, According ...

    www.aol.com/1-high-protein-snack-better...

    In one study, people who ate roughly 1 to 2 ounces of walnuts daily for one year experienced a significant decrease in LDL cholesterol. Nutrients to Focus On for Heart Health Plant-Based Protein.

  9. Trastuzumab deruxtecan - Wikipedia

    en.wikipedia.org/wiki/Trastuzumab_deruxtecan

    Participants were randomized 1:1 to receive either trastuzumab deruxtecan or trastuzumab emtansine by intravenous infusion every three weeks until unacceptable toxicity or disease progression. [16] Randomization was stratified by hormone receptor status, prior treatment with pertuzumab, and history of visceral disease. [16]